asialoerythropoietin

**Asialoerythropoietin** is a non-hematopoietic, recombinant derivative of human erythropoietin (EPO) in which all sialic acids have been enzymatically removed[2][3][6]. Unlike native or recombinant human EPO, asialoerythropoietin does not stimulate erythropoiesis (production of red blood cells) but retains and enhances tissue-protective and neuroprotective capabilities, particularly via activation of the erythropoietin receptor (EPO-R) in neural and other non-hematopoietic tissues[2][3][6][1]. It has demonstrated efficacy in animal models of cerebral ischemia, stroke, spinal cord injury, and peripheral neuropathy, and shows tissue protection in the heart, kidney, liver, and pancreas[2][3][1][10]. Asialoerythropoietin’s inability to increase hematocrit or platelet aggregability makes it an attractive candidate for conditions where erythropoietic activity poses a risk, such as stroke, nervous system injury, and ischemic events[2][4]. It can be produced from mammalian cells by enzymatic desialylation or via plant-based glycoengineering[1][3][6].

Other names

asialo-EPOasialo-rhuEPOasialoerythropoietin